Clinical trials: Movement Abnormalities
Parkinson Disease
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
The main objective of the study is to explore firstly, then further evaluate and confirm the efficacy between Pramipexole Sustained Release (SR) versus Pramipexole Immediate Release (IR) on nocturnal symptoms (as measured by the…
- Trial name
- NCT03521635
- Testing
- Pramipexole SR, Pramipexole IR
- Where
- 12 sites in China
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Tardive Dyskinesia
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one…
- Trial name
- RE-Kinect (NCT03062033)
- Where
- 34 sites in United States
- Volunteers
- 70 people
- Sponsor
- Neurocrine Biosciences
Idiopathic Parkinson's Disease
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
The objective of this study is to compare the pharmacokinetics and pharmacodynamics of IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa controlled-release tablets in subjects with idiopathic…
- Trial name
- NCT00279825
- Testing
- IPX054 200 mg, IPX054 250 mg, CD-LD IR
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1 mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.
- Trial name
- NCT02337738
- Testing
- TVP-1012 1mg, TVP-1012 0.5mg
- Where
- 57 sites in Japan
- Volunteers
- 404 people
- Sponsor
- Takeda
Parkinson's Disease
PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy
Non-Ergot Dopamine agonists are meanwhile the drugs of first-choice in the treatment of Parkinson's disease. The receptor profile of the non-ergot dopamine-agonist piribedil is unique.
- Trial name
- PIR-008/K (NCT01519856)
- Testing
- piribedil (Clarium)
- Where
- Germany
- Volunteers
- 908 people
- Sponsor
- Desitin Arzneimittel GmbH
Parkinson's Disease
Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations
The primary objective of the study is to compare the adhesiveness of two different patch formulations of rotigotine using patch size 40 cm2, under the assumption that both patch formulations show similar adhesiveness properties.
- Trial name
- NCT01338896
- Testing
- Rotigotine transdermal patch
- Where
- 16 sites in Austria, Germany and 1 more
- Volunteers
- 56 people
- Sponsor
- UCB Pharma
Parkinson Disease (PD)
VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
This study is testing a new oral medication called VG081821AC to see if it can help improve movement symptoms in people with early to mid-stage Parkinson's disease.
- Trial name
- NCT07725562
- Testing
- VG081821AC
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Zhejiang Vimgreen Pharmaceuticals, Ltd.
Progressive Supranuclear Palsy, PSP
AMX0035 and Progressive Supranuclear Palsy
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an…
- Conditions
- Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
- Trial name
- ORION (NCT06122662)
- Testing
- AMX0035
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 139 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Dementia With Lewy Bodies
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB.
- Trial name
- NCT05869669
- Testing
- Neflamapimod
- Where
- 40 sites in United States, Netherlands and 1 more
- Volunteers
- 159 people
- Sponsor
- EIP Pharma Inc
Tourette Syndrome
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS.
- Trial name
- ALLEVIA2 (NCT06315751)
- Testing
- Gemlapodect
- Where
- 46 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Noema Pharma AG
Parkinson's Disease
Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy
The purpose of this study is to evaluate the efficacy of KW-6500 versus placebo when administered as a subcutaneous injection at the individualized maintenance dose level in an OFF state in Parkinson's disease patients with motor…
- Trial name
- NCT00610103
- Testing
- apomorphine hydrochloride
- Where
- 4 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease, Parkinson's Disease
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
Ropinirole Hydrochloride (ROP) was granted approval for the treatment of Parkinson's Disease (PD) on 20 October 2006. ROP is expected to be used for a long term in clinical practice.
- Trial name
- NCT00485069
- Testing
- ROP, ROP+L-Dopa
- Where
- 22 sites in Japan
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Wilson's Disease
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
Decentralized study to assess patient reported treatment satisfaction comparing their current standard-of-care Wilson's Disease (WD) treatment with a new once-daily Trientine (TETA) 4HCl formulation.
- Trial name
- NCT07010575
- Testing
- New TETA 4HCl Formulation, Standard of Care
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Orphalan
Parkinson Disease
Temporally Optimized Patterned Stimulation (TOPS®) Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease
This study will test newly developed stimulation settings called Temporally Optimized Patterned Stimulation or TOPS, which can be used with an already implanted deep brain stimulation system.
- Trial name
- TOPS (NCT04390867)
- Testing
- TOPS1 DBS, TOPS2 DBS, TOPS3 DBS
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Deep Brain Innovations LLC
Parkinson Disease
Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers
This is a non-drug study in patients with Parkinson's Disease (PD) and healthy volunteers to process and analyze their blood and optional cerebrospinal fluid (CSF) samples ex vivo, or outside of their body, to further develop…
- Trial name
- IRIS-CLE-LRRK2 (NCT05837130)
- Testing
- Blood sample collection and an optional cerebrospinal fluid (CSF) collection, Blood sample collection
- Where
- 4 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Servier
Progressive Supranuclear Palsy (PSP)
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT03391765
- Testing
- ABBV-8E12
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 142 people
- Sponsor
- AbbVie
Parkinson's Disease
Levodopa Concentration Profile With Stalevo 75/125 mg
The purpose of this study is to confirm that the dose levels and dosing frequency utilising the new Stalevo strengths would result into more stable levodopa plasma levels.
- Trial name
- NEWSTA (NCT01070628)
- Testing
- Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa)
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease
A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
The purpose of this study is to investigate the effect of BIA 9-1067 on the levodopa pharmacokinetics when administered in combination with immediate release levodopa/carbidopa or levodopa/benserazide in Parkinson's Disease (PD)…
- Trial name
- NCT01568034
- Testing
- BIA 9-1067, Levodopa/Carbidopa, Levodopa/Benzerazide
- Where
- 3 sites in Portugal, Romania and 1 more
- Volunteers
- 10 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease
This is a single-center, open label study evaluating the acute effect of caloric vestibular stimulation on UPDRS motor scores in Parkinson's Disease patients.
- Trial name
- NCT02134795
- Testing
- TNM Device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Scion NeuroStim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.